Coree Wuhan

We are committed to improving the efficiency, safety and sustainability of the pharmaceutical supply chain and providing customers and patients with quality products and services. We believe that continuous innovation is the core driving force for the company's development and the key to maintaining our leading position in the pharmaceutical field.

Beginning of
journey
The deceased Chairman Sung-ki Lim the founder of Hanmi Pharmaceutical, developed infant microbiome products and launched them to the market; expanded into the Chinese market (1996)
Establish microbiome
research foundation
Established the Coree Group Microbiome Research Institute and launched the microbiome-based Ofmom brand
Enhancement of
R&D
Establishment of COREE Italy AAT Research Institute, and build global R&D infrastructure and clinical network
Innovative microbiome
research
Collaboration between the Institutes of Genetics and Microbiome
Develop therapeutic strains through multi-omics research Develop prevention, treatment, and management solutions based on the microbiome

We have a nationwide supply and marketing network system as well as global R&D network.

231,265: clinics, including clinics, service stations, outpatient departments, etc…

Shou-yuan, Lee, Ph.D.

Director of the Microbiome Research Institute Consultant of Coree Group Microbiome Research Institute Beijing Hanmei Pharmaceutical Mamiai Probiotics Team Consultant

#Probiotics R&D, CDO
Prof.
Antonio Gasbarrini

Dean of the School of Medicine/Surgery, Sacred Heart University College A.Gemelli Director of Internal Medicine and Gastrointestinal Endoscopy Research at IRCCS University Hospital

#Gastrointestinal #Gut Microbes #Digest system diseases
Prof. Angelo Vittorio
Zambrini

Tecnoalimenti S.C.p.A President

#Probiotics R&D, CDO
Prof.
Dr.LORENZO MORELLI

COREE Italy Technical Advisor
Marina Elli, Ph.D.

Dx&Vx Scientific Advisor COREE Italy R&D Director